Head and neck cancer affects about 66 000 patients and causes 15 000 deaths annually in the US.1 More than 90% of cases are due to squamous cell carcinoma (SCC) that originates from the oral cavity, oropharynx, and larynx.2 The epidemiology of SCC of the head and neck (HNSCC) has shifted in recent decades, with an increase in human papillomavirus (HPV)–associated SCC of the oropharynx and a decrease in tobacco- and alcohol-associated SCC,3 with important race and sex differences in access to care and survival.4 Patients often present with locoregionally advanced disease, leading to important morbidities of speech, deglutition, and cosmesis that stem both from the disease and its treatment, which often involves a combination of surgery, chemotherapy, and radiation. Most recurrences occur in the first few years after treatment. The National Comprehensive Cancer Network (NCCN) recommends integration of primary care in survivorship care within 1 year of completion of treatment, complementary to the oncology team. There has been an increased focus and maturation of the concept of cancer survivorship since previous efforts.4 The current guidelines offer a concise summary of best practices for this integrated care.